Corporate Presentation - Jubilant Bhartia Group

Market positions based on Company analysis & estimates12PharmaceuticalsActive Pharmaceutical Ingredients• Provider of bulk drugs to generic pharmaceuticals companies• Focus on therapeutic segments - CVS, CNS, Gastro-intestinal and anti-infectivesGlobal leadership in APIs - Carbamezepine, Citalopram,Donepezil, Irbesartan, Lamotrigine, Meclizine,Oxcarbazepine and ValsartanGenerics• Provider of high quality finished dosage forms (tablets and capsules) Globally among Top 3 in several Generic Dosage FormsSpecialty Pharmaceuticals• Development, manufacture and marketing of radiopharmaceutical products for diagnostic andtherapeutic use• Major therapeutic and diagnostic extracts for allergy derived from pollens, animals and stinginginsects venomsLeading market share positions in Four therapeutic andimaging Nuclear Medicine products in North AmericaLeading No. 2 Allergy Therapy Company in the USAContract Manufacturing• CMO services for Lyophilized products, liquid fills, biologics, suspensions and WFI / diluent andclinical trial quantities• CMO services for ointment, cream and liquidDrug Discovery & Development Solutions• Providing integrated Drug Discovery and Development Solutions to global pharmaceuticals andbiotech companies• Discovery Research: Target to IND, functional services, medicinal chemistry and scale upsynthesis• Clinical Research: Integrated from Phase I to Phase IV in US, Europe and India• JV with Lilly for managing drug development from Pre-clinical to Phase II – proof of conceptLeading pharmaceutical contract manufacturer ofmultiple sterile and non-sterile dosage forms in NorthAmericaLeadership in Integrated Drug Discovery andDevelopment solutions with location across India,Europe and the US.Healthcare• A hub & spoke model to provide affordable high-quality healthcare services in West Bengal,India, plans to set up total of 1000 beds with 165 beds operational currentlyUnique affordable healthcare model12